Arpida’s Iclaprim Labeling Would Likely Include QTc Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to file an NDA for the Zyvox competitor in 2007 and launch in 2008.
You may also be interested in...
Arpida’s Novel Anti-Infective Iclaprim Buoyed By Second Phase III Trial
Swiss firm plans regulatory submission in the U.S. by the end of the year, launch in 2008.
Arpida’s Novel Anti-Infective Iclaprim Buoyed By Second Phase III Trial
Swiss firm plans regulatory submission in the U.S. by the end of the year, launch in 2008.
Cubicin Indication Expands To Cover S. Aureus Bacteremia
Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.